Hematologic Malignancies/BMT

自上一次竞争性更新以来，血液肿瘤和骨髓移植项目（前身为白血病-淋巴瘤/BMT项目）在实验室和临床/转化研究方面有了很大的扩展。多名研究者加入了该计划，并启动了白血病生物学研究项目（白血病和淋巴瘤的基因组学/蛋白质组学和表观遗传靶向），白血病、骨髓瘤和淋巴瘤靶向治疗的开发（表观遗传、MDM- 2、Notch/泛素化和/激酶途径）和预防同种异体BMT后复发。此外，基础生物学的前沿研究和骨髓移植后造血干细胞和移植物抗宿主病的杰出转化工作得到进一步扩展。同行评审的资金数额，包括联邦和非联邦（白血病淋巴瘤协会，达蒙鲁尼恩等）大幅增加。同行审查的资金从上次审查时的520万美元增加到1 340万美元，增加了一倍多，其中包括280万美元的NCI直接资金。在此期间，来自七个部门的36名成员出版了177份出版物，其中25.4%是计划内的，37.3%是计划间的。临床研究受益于招募杰出的临床研究者，导致研究者生成的治疗研究增加，我们还扩大了与行业的合作，以研究新药。总的来说，这些举措正在导致临床试验患者的增加。

Since the last competing renewal, the Hematologic Malignancies and Bone Marrow Transplantation Program, formerly the Leukemia-Lymphoma/BMT Program, has greatly expanded in laboratory based and clinical/'translational research. Multiple Investigators have joined the Program and research projects have been Initiated In leukemia biology (the genomics/ proteomics and epigenetic targeting of leukemia and lymphoma), development of targeted therapies for leukemia, myeloma and lymphoma (epigenetic, MDM- 2, Notch/ ubiquitination and/ kinase pathways) and prevention of relapse after allogeneic BMT, In addition, the cutting edge research in basic biology and outstanding translational efforts in hematopoietic stem cells and graft-versus-host disease after BMT have been further expanded. The amount of peer reviewed funding, both federal and non-federal (Leukemia Lymphoma Society, Damon Runyon, etc.) has substantially increased. Peer-reviewed funding has more than doubled from $5.2 million at the last review to $13.4 million, including $2.8 million in NCI funding, in direct funding. Over this grant period, the 36 members of this program from seven departments have published 177 publications of which 25.4% are intra-programmatic and 37.3% are inter-programmatic. Clinical research has benefitted from the recruitment of prominent clinical investigators leading to an increase in Investigator-generated therapeutic studies, We have also expanded collaborations with industry to study novel drugs. Collectively, these Initiatives are leading to enhanced accrual of patients on clinical trials.